656 related articles for article (PubMed ID: 20666193)
1. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
Viera MH; Perez OA; Patel JK; Jones I; Berman B
Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
[TBL] [Abstract][Full Text] [Related]
2. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
3. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
Wolf R; Matz H; Marcos B; Orion E
Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
[TBL] [Abstract][Full Text] [Related]
4. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
[No Abstract] [Full Text] [Related]
5. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
6. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
[TBL] [Abstract][Full Text] [Related]
7. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.
Darlenski R; Kazandjieva J; Tsankov N
Clin Dermatol; 2015; 33(5):538-41. PubMed ID: 26321400
[TBL] [Abstract][Full Text] [Related]
8. [Stevens-Johnson syndrome, toxic epidermal necrolysis and phenytoin. Factors linked to a higher risk].
Gómez-Criado MS; Ayani I; León-Colombo T; Ramos ML; Reneses MJ
Rev Neurol; 2004 Jun 1-15; 38(11):1056-60. PubMed ID: 15202085
[TBL] [Abstract][Full Text] [Related]
9. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
10. [Severe delayed drug hypersensitivity reactions].
Maniu CM; Buss G; Feldmeyer L; Spertini F; Ribi C
Rev Med Suisse; 2013 Apr; 9(382):803-4, 806-11. PubMed ID: 23667969
[TBL] [Abstract][Full Text] [Related]
11. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective.
Todd G
Dermatol Clin; 2006 Oct; 24(4):459-72, vi. PubMed ID: 17010776
[TBL] [Abstract][Full Text] [Related]
12. [Item 181--Iatrogenesis. Diagnosis and prevention: drug-induced dermatoses].
CEDEF
Ann Dermatol Venereol; 2012 Oct; 139(11 Suppl):A172-8. PubMed ID: 23176842
[No Abstract] [Full Text] [Related]
13. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
14. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
16. The DRESS syndrome: the great clinical mimicker.
Fleming P; Marik PE
Pharmacotherapy; 2011 Mar; 31(3):332. PubMed ID: 21361742
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases.
Lee HY; Tey HL; Pang SM; Thirumoorthy T
Lupus; 2011 May; 20(6):647-52. PubMed ID: 21148602
[TBL] [Abstract][Full Text] [Related]
18. [Adverse cutaneous reactions to drugs in neurology].
Redondo Bellón P
Rev Neurol; 1997 Sep; 25 Suppl 3():S309-19. PubMed ID: 9273176
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis after cranial radiotherapy and phenytoin treatment.
Oner Dincbas F; Yörük S; Demirkesen C; Uzel O; Koca S
Onkologie; 2004 Aug; 27(4):389-92. PubMed ID: 15347896
[TBL] [Abstract][Full Text] [Related]
20. Life-threatening acute adverse cutaneous drug reactions.
Wolf R; Orion E; Marcos B; Matz H
Clin Dermatol; 2005; 23(2):171-81. PubMed ID: 15802211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
